A coalition from the UK’s health sector say Brexit negotiators have a responsibility to protect 500 million patients on both sides of the Channel. The group is calling on both sides to make patients and public health central to the Political Declaration for the future relationship between the UK...
Responding to the announcement of the Withdrawal Agreement and political declaration on the UK’s future relationship with the EU, the Association of the British Pharmaceutical Industry welcomes an important step towards securing a Brexit deal.
The Taskforce for Lung Health – which the ABPI is a member - is today calling for an inexpensive breath test to be much more widely used in GP practices, community health services and hospitals to improve the diagnosis of lung disease.
Tens of thousands of lives could be saved by pioneering research to detect deadly diseases before symptoms even appear, thanks to a new collaboration between the government and the Life Sciences Industry.
The Prime Minister has today announced that the parliamentary vote on Brexit has been delayed. In response, the ABPI has emphasised the need to avoid a 'no-deal' situation.
A new report from Deloitte suggests that projected returns on research and development investment for the 12 leading pharmaceutical companies in the world has fallen to 1.9 per cent, citing an increase in the average cost to develop and win marketing approval for new medicines behind the declining...
The Government has today published its plans for the UK’s future immigration system.
The NHS has today published its Long Term Plan setting out what it will be prioritising in the future.
The ABPI has named Elliot Dunster as its Executive Director of Communications.
The Association of the British Pharmaceutical Industry (ABPI) – the trade group representing the branded pharmaceutical industry in the UK – has responded to the outcome of the meaningful vote on the Withdrawal Agreement and Political Deceleration.
The UK Government has launched their National Action Plan to tackle antimicrobial resistance. It sets out how Britain will achieve its new 20-year vision for a world in which AMR is contained and controlled by 2040, covering health, animals, the environment and the food chain.